Shares in Medivir AB dropped by 21.25 percent Tuesday on news that partner Boehringer Ingelheim GmbH opted to discontinue development of the HIV drug MIV-310 (alovudine) following a Phase IIa trial in which the compound failed to attain a target efficacy level. (BioWorld International)
DUBLIN, Ireland - Confirmation of a second case of progressive multifocal leukoencephalopathy (PML) among the 1,171 multiple sclerosis patients receiving Tysabri (natalizumab) in combination with Avonex (interferon beta-1a) sent shares of Elan Corp. plc and Biogen Idec Inc. further downward last Friday. (BioWorld International)
DUBLIN, Ireland - Confirmation of a second case of progressive multifocal leukoencephalopathy (PML) among the 1,171 multiple sclerosis patients receiving Tysabri (natalizumab) in combination with Avonex (interferon beta-1a) sent shares of Elan Corp. plc and Biogen Idec Inc. further downward last Friday. (BioWorld International)
Speedel Group raised CHF47.8 million (US$41 million) in equity funding, most of it from the same network of private investors and specialist investment funds that have supported the company since its formation in 1998. (BioWorld International)
